Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0615-8330

5 FDA label images from Ncs Healthcare Of Ky, Llc Dba Vangard Labs · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0615-8330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Divalproex Sodium Er Tabs 8330 1)

Structure (Divalproex Sodium Er Tabs 8330 1)
Chemical structure of the active ingredient Divalproex Sodium, depicting its molecular arrangement with sodium ion (Na+), carbon, oxygen, and hydrogen atoms, and repeating units indicated by the subscript n.*
FDA Label Image

Figure1 (Divalproex Sodium Er Tabs 8330 2)

Figure1 (Divalproex Sodium Er Tabs 8330 2)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo across a percentage of patients. The vertical axis shows percentage reduction in CPS rate from -100% to 100%, with annotations for 'Improvement' and 'Worsening'. The horizontal axis shows the percentage of patients from 0 to 100%. The graph illustrates that patients taking Divalproex Sodium generally experience greater improvements than those taking placebo.*
FDA Label Image

Figure2 (Divalproex Sodium Er Tabs 8330 3)

Figure2 (Divalproex Sodium Er Tabs 8330 3)
A cumulative percentage plot comparing the percentage reduction in CPS (Complex Partial Seizure) rate for patients treated with high dose and low dose divalproex sodium delayed-release tablets. The graph shows improvement versus worsening along the vertical axis and percentage of patients along the horizontal axis, illustrating treatment effects on seizure rate reduction.*
FDA Label Image

Figure3 (Divalproex Sodium Er Tabs 8330 4)

Figure3 (Divalproex Sodium Er Tabs 8330 4)
A bar chart comparing placebo with Divalproex Sodium Extended-Release Tablets, showing a higher value for the tablets (1.2) versus the placebo (0.6). The chart includes labeled bars and a legend indicating the groups.*
FDA Label Image

Principal Display Panel (Divalproex Sodium Er Tabs 8330 5)

Principal Display Panel (Divalproex Sodium Er Tabs 8330 5)
Label for Divalproex Sodium extended-release tablets, USP 500 mg, film-coated, extended-release oral tablets. The label shows the product name, strength, dosage form, and manufacturer information: labeled to NCS HealthCare of KY, LLC dba Vangard Labs, packaged by Vanguard in Glasgow, KY. It includes lot number 8330 and quantity 30 tablets. Instructions indicate storage at 20°-25°C and that the product is for institutional use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.